Predict your next investment

MOBILE & TELECOMMUNICATIONS | Mobile Software & Services / Conferencing & Communication
firsttouchteam.com

See what CB Insights has to offer

Board of Directors

1

Private Group Networks Board of Director

1 Board of directors

Private Group Networks has 1 board of directors, including Somu Subramaniam.

Name

Firm

Work History

Other Seats

Somu Subramaniam

Mr. Subramaniam is the Co-Founder and Managing Partner of New Science Ventures, serving on the Board of Directors of Achronix Semiconductor Corporation, Alexar Therapeutics, Ario Pharmaceuticals, Cambridge Epigenetix, Dali Wireless, Dezima Pharma, Juventas Therapeutics, Oxyrane, Resolve Therapeutics, TigerText, Vaultive, and iCAD. Mr. Subramaniam also served on the boards of Ception (acquired by Cephalon), BioVex (acquired by Amgen), Lightwire (acquired by Cisco) and K2M (acquired by Welsh Carson). Prior to founding NSV, Mr. Subramaniam was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries. At McKinsey, he was leader of the Strategy Practice, the Technology Practice, the Biotechnology Group and the Healthcare Practice. He also served on the firm’s Investment Committee and led its Equity Portfolio Committee. Mr. Subramaniam holds a BTech degree from the Indian Institute of Technology and an MBA from Harvard Business School.

Achronix, BioVex, Celleration, iCAD, Juventas Therapeutics, Lightwire, MagSil, PerceptiMed, Proterixbio, Receptor Biologix, Resolve Therapeutics, RF Arrays, TigerConnect, Trellis Bioscience, Vaultive, and Vorago Technologies

Name

Somu Subramaniam

Firm

Work History

Mr. Subramaniam is the Co-Founder and Managing Partner of New Science Ventures, serving on the Board of Directors of Achronix Semiconductor Corporation, Alexar Therapeutics, Ario Pharmaceuticals, Cambridge Epigenetix, Dali Wireless, Dezima Pharma, Juventas Therapeutics, Oxyrane, Resolve Therapeutics, TigerText, Vaultive, and iCAD. Mr. Subramaniam also served on the boards of Ception (acquired by Cephalon), BioVex (acquired by Amgen), Lightwire (acquired by Cisco) and K2M (acquired by Welsh Carson). Prior to founding NSV, Mr. Subramaniam was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries. At McKinsey, he was leader of the Strategy Practice, the Technology Practice, the Biotechnology Group and the Healthcare Practice. He also served on the firm’s Investment Committee and led its Equity Portfolio Committee. Mr. Subramaniam holds a BTech degree from the Indian Institute of Technology and an MBA from Harvard Business School.

Other Seats

Achronix, BioVex, Celleration, iCAD, Juventas Therapeutics, Lightwire, MagSil, PerceptiMed, Proterixbio, Receptor Biologix, Resolve Therapeutics, RF Arrays, TigerConnect, Trellis Bioscience, Vaultive, and Vorago Technologies

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.